MorphoSys AG (WBO:MOR) 3-Year Book Growth Rate : -59.00% (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is MorphoSys AG 3-Year Book Growth Rate?

MorphoSys AG's Book Value per Share for the quarter that ended in Dec. 2023 was €1.30.

During the past 12 months, MorphoSys AG's average Book Value per Share Growth Rate was -71.70% per year. During the past 3 years, the average Book Value per Share Growth Rate was -59.00% per year. During the past 5 years, the average Book Value per Share Growth Rate was -37.30% per year. During the past 10 years, the average Book Value per Share Growth Rate was -14.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of MorphoSys AG was 37.10% per year. The lowest was -59.00% per year. And the median was 7.20% per year.

Competitive Comparison of MorphoSys AG's 3-Year Book Growth Rate

For the Biotechnology subindustry, MorphoSys AG's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MorphoSys AG's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MorphoSys AG's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where MorphoSys AG's 3-Year Book Growth Rate falls into.

MorphoSys AG 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

MorphoSys AG (WBO:MOR) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

MorphoSys AG 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of MorphoSys AG's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

MorphoSys AG (WBO:MOR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MorphoSys AG (WBO:MOR) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

MPSYF:USA MOR:USA 1MOR:Italy MORd:UK 0NDV:UK MOR:Germany

Address

Semmelweisstrasse 7, Planegg, BY, DEU, 82152

Website

https://www.morphosys.com

MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.